A couple of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made huge purchases on Tuesday. Altogether, these funds bought over 850,000 shares of UiPath Inc. (NYSE: PATH) on Tuesday, as the price of these ETFs gained less than 1% on Tuesday. Note that these funds are still up handily in the last year.
ARK Genomic Revolution ETF (NYSEARCA: ARKG) bought 291,229 shares of UiPath, and ARK Innovation ETF (NYSEARCA: ARKK) bought 566,900 shares. At Tuesday’s closing price, this would have valued these purchases at roughly $59.1 million. Even though this is a small fraction of the total holdings, every little bit counts. ARKG is up 84% in the past year and ARKK is up 92%.
Check out all of ARK Invest’s buys for Tuesday:
Fund | Ticker | Company | Shares |
---|---|---|---|
ARKG | IONS | Ionis Pharmaceuticals | 268,748 |
ARKG | PATH | UIPath | 291,229 |
ARKK | PATH | UIPath | 566,900 |
ARKQ | KTOS | Kratos Defense & Security Solutions | 50,625 |
ARKQ | BZ | Kanzhun | 109,718 |
ARKW | BZ | Kanzhun | 101,005 |
ARKW | VUZI | Vuzix | 232,063 |
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.
Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE
Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply
clicking here you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.